Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

112.51 +16.70 (+17.43%)
Streaming Delayed Price Updated: 10:39 AM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
67 68 Next >
Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say
Australian health authorities have recommended against a fifth COVID-19 vaccine shot despite average daily cases having been 47% higher last week than the week before, said Health Minister Mark Butler... 
Via Benzinga
Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride
Its booster led to a 15.1-fold increase in BA.4- and BA.5-blocking antibodies. 
Via Investor's Business Daily
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his... 
Via FinancialNewsMedia
BioNTech Plans To Set Up Singapore Based mRNA Plant By End Of 2023
Via Benzinga
This COVID-19 Vaccine Stock Has More to Offer
The vaccine revenue was nice, but it's time to look ahead. 
Via The Motley Fool
BioNTech SE (BNTX) Q3 2022 Earnings Call Transcript
BNTX earnings call for the period ending September 30, 2022. 
Via The Motley Fool
BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
From BioNTech SE
Via GlobeNewswire
Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows
Via Benzinga
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Exposures COVID-19 Product Safety
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
Learn more about Organicell Regenerative Medicine, Inc.from this latest report. 
Via TheNewswire.com
Exposures COVID-19 Product Safety
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
From BioNTech SE
Via GlobeNewswire
2 Top Healthcare Stocks to Buy Right Now
These two dividend stocks offer 3%-plus dividend yields that are secure. 
Via The Motley Fool
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
During the peak of the deadly COVID-19 pandemic, one novel therapeutic that seems to have played an important role in helping save lives was Organicell Regenerative Medicine Inc.’s (OTCMKTS:... 
Via Benzinga
Return To Office: Pfizer To Enforce 2-3 Days In Office Starting January
Pfizer Inc's (NYSE: PFE) CEO Albert Bourla said the U.S. employees would have to return to their workplaces two to three days a week starting in January. 
Via Benzinga
The 7 Best Pharma Stocks to Buy Now
Investors searching for gains in the current market storm should consider taking a position in some of the best pharma stocks. 
Via InvestorPlace
Got $2,000? 2 Fantastic Stocks to Buy No Matter What the Market Does Next
These stocks both have non-cyclical businesses that can drive growth in a wide variety of markets. 
Via The Motley Fool
BioNTech Takes A Hit Despite Doubling Profit Views, Raising 2022 Outlook
BioNTech doubled profit expectations in the third quarter and raised its outlook. 
Via Investor's Business Daily
Meta Goes Twitter Way With Layoffs, Twitter Might Want Some People Back After Firing Them, Coal Miners Terminate $6B Combination Discussions: Top Stories Monday, Nov. 07
Wall Street Journal 
Via Benzinga
BioNTech Posts About 50% Drop In Q3 Sales and Profits Amid Falling Demand For COVID-19 Shots
Via Benzinga
Risk Appetites Survive China Keeping Zero COVID Policy
Chinese officials denied plans to end the zero-COVID policy and after a brief wobble, risk assets have traded better. Asia Pacific equities rallied, led by Hong Kong and mainland stocks that trade in... 
Via Talk Markets
Recap: BioNTech Q3 Earnings
BioNTech (NASDAQ:BNTX) reported its Q3 earnings results on Monday, November 7, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings BioNTech beat estimated earnings by... 
Via Benzinga
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex
Deals, financings, trials and approvals in Chinese biotech/biopharma this week. 
Via Talk Markets
Did Vaccine Stocks Just Get Their Last Boost?
Some positive news sent their share prices higher, but biotech companies will need to find other ways to make money. 
Via The Motley Fool
This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters
Pfizer and BioNTech tested their updated Covid booster against the original shot. 
Via Investor's Business Daily
BioNTech's COVID-19 Vaccine Becomes First Foreign Shot To Be Available In Chinese Market
German Chancellor Olaf Scholz agreed to allow expatriates in China to use BioNTech SE (NASDAQ: BNTX) made COVID-19 vaccine. BioNTech would be the first non-Chinese coronavirus vaccine in China, as... 
Via Benzinga
Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity
Via Benzinga
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.